2014
Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS‐MS
Fitian A, Nelson D, Liu C, Xu Y, Ararat M, Cabrera R. Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS‐MS. Liver International 2014, 34: 1428-1444. PMID: 24661807, PMCID: PMC4169337, DOI: 10.1111/liv.12541.Peer-Reviewed Original ResearchMeSH Keywords12-Hydroxy-5,8,10,14-eicosatetraenoic AcidAmino AcidsBile Acids and SaltsCarcinoma, HepatocellularChromatography, High Pressure LiquidDicarboxylic AcidsGas Chromatography-Mass SpectrometryHepatitis CHumansHydroxyeicosatetraenoic AcidsLiver CirrhosisLiver NeoplasmsMetabolomeMetabolomicsMultivariate AnalysisROC CurveSphingosineTandem Mass SpectrometryXanthineConceptsPresence of HCCHepatocellular carcinomaUPLC/MS-MSHCC patientsMetabolic alterationsHepatitis C cirrhosisBile acid metabolismHallmarks of HCCMetabolomic profilingAcid metabolismReceiver operator characteristic analysisOperator characteristic analysisGlobal metabolic alterationsMetabolic pathway disturbancesC cirrhosisHCV cirrhosisHepatitis CMetabolic disturbancesHCC developmentSerum metabolomeHealthy volunteersEicosanoid pathwayCirrhosisPathway disturbancesBile acids
2012
Guardian and Selective Killer: The Versatile Functions of TLR3 in Hepatocellular Carcinoma
Liu C. Guardian and Selective Killer: The Versatile Functions of TLR3 in Hepatocellular Carcinoma. Journal Of The National Cancer Institute 2012, 104: 1780-1782. PMID: 23197496, PMCID: PMC3514168, DOI: 10.1093/jnci/djs475.Peer-Reviewed Original ResearchCC genotype donors for the interleukin‐28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant
Firpi R, Dong H, Clark V, Soldevila‐Pico C, Morelli G, Cabrera R, Norkina O, Shuster J, Nelson D, Liu C. CC genotype donors for the interleukin‐28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant. Liver International 2012, 33: 72-78. PMID: 23107586, PMCID: PMC3518691, DOI: 10.1111/liv.12013.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntiviral AgentsBiopsyFemaleFloridaGenotypeHepatitis CHumansInterferonsInterleukinsKaplan-Meier EstimateLiver CirrhosisLiver TransplantationLogistic ModelsMaleMiddle AgedMultivariate AnalysisOdds RatioPolymorphism, Single NucleotideProportional Hazards ModelsRecurrenceRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTissue DonorsTreatment OutcomeConceptsSustained viral responseInterferon-based therapyLiver transplant patientsCC genotypeRecurrent HCVLiver transplantTransplant patientsIL-28B single nucleotide polymorphismInterleukin (IL) 28B single nucleotide polymorphismsAdult liver transplant patientsPost-transplant HCV recurrenceHepatitis C populationIL-28B genotypeIL-28B polymorphismsInterleukin 28B (IL28B) polymorphismsStrongest pretreatment predictorOverall clinical outcomeBetter treatment responseSingle nucleotide polymorphismsHCV recurrenceHCV patientsHCV therapyLiver transplantationHepatitis COverall survivalIron Regulator Hepcidin Exhibits Antiviral Activity against Hepatitis C Virus
Liu H, Le Trinh T, Dong H, Keith R, Nelson D, Liu C. Iron Regulator Hepcidin Exhibits Antiviral Activity against Hepatitis C Virus. PLOS ONE 2012, 7: e46631. PMID: 23110054, PMCID: PMC3478283, DOI: 10.1371/journal.pone.0046631.Peer-Reviewed Original ResearchConceptsHCV infectionHepcidin expressionSerious chronic liver diseaseAntiviral activityHepatitis C viral infectionHepcidin expression levelsChronic HCV infectionChronic liver diseaseC viral infectionHepatitis C virusDirect antiviral activityIntracellular antiviral stateHepatocellular carcinoma progressionInnate antiviral defenseLiver diseaseC virusAntiviral effectHCV replicationIron overloadHepatocellular carcinomaExhibit antiviral activityHCVViral infectionSuppressive effectAmino acid peptideNanoparticle-based artificial RNA silencing machinery for antiviral therapy
Wang Z, Liu H, Yang S, Wang T, Liu C, Cao Y. Nanoparticle-based artificial RNA silencing machinery for antiviral therapy. Proceedings Of The National Academy Of Sciences Of The United States Of America 2012, 109: 12387-12392. PMID: 22802676, PMCID: PMC3412013, DOI: 10.1073/pnas.1207766109.Peer-Reviewed Original ResearchConceptsFundamental gene regulatory mechanismsHepatitis C virusGene regulatory mechanismsCultured cellsTarget RNA cleavageSequence-specific mannerCellular interferon responseFunctional genomicsHuman hepatoma cellsRNA interferenceArtificial RNARegulatory mechanismsMouse modelRNA cleavageCultured human hepatoma cellsSpecific mannerHCV RNA levelsRNAXenotransplantation mouse modelHepatoma cellsInterferon responsePotent antiviral activityRNA levelsMachineryProteinase activity
2009
Focal Distribution of Hepatitis C Virus RNA in Infected Livers
Stiffler J, Nguyen M, Sohn J, Liu C, Kaplan D, Seeger C. Focal Distribution of Hepatitis C Virus RNA in Infected Livers. PLOS ONE 2009, 4: e6661. PMID: 19688046, PMCID: PMC2722721, DOI: 10.1371/journal.pone.0006661.Peer-Reviewed Original ResearchMeSH KeywordsBlotting, WesternCohort StudiesGene DosageHepacivirusHepatitis CHumansInterferonsLiverRNA, ViralConceptsHepatitis C virusHCV RNA levelsHCV RNAHCV replicationRNA levelsBiopsy samplesHCV RNA copy numbersIntrahepatic HCV-RNA levelsISG levelsHepatitis C virus RNAWhole liver sectionsC virus RNAViral RNA levelsFocal distributionInnate immune responseRNA copy numberHCV infectionC virusInfected patientsInfected hepatocytesInterferon betaImmune responseInfected liverLiver sectionsIFNbeta expression
2007
Hepatitis C Virus Triggers Apoptosis of a Newly Developed Hepatoma Cell Line Through Antiviral Defense System
Zhu H, Dong H, Eksioglu E, Hemming A, Cao M, Crawford J, Nelson D, Liu C. Hepatitis C Virus Triggers Apoptosis of a Newly Developed Hepatoma Cell Line Through Antiviral Defense System. Gastroenterology 2007, 133: 1649-1659. PMID: 17983809, DOI: 10.1053/j.gastro.2007.09.017.Peer-Reviewed Original ResearchConceptsTumor necrosis factor-related apoptosis-inducing ligandHCV infectionViral infectionHepatoma cell lineHCV isolatesJFH-1New hepatoma cell lineViral replicationCell linesMechanisms of HCVAcute HCV infectionChronic viral infectionsPathogenesis of HCVNovel human hepatoma cell lineInterferon response factor 3Antiviral defense systemNecrosis factor-related apoptosis-inducing ligandType I interferon inductionFactor-related apoptosis-inducing ligandExpression of interferonHost immune systemHepatocellular carcinoma tissuesI interferon inductionDeath receptor 5Induction of interferon
2005
Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication
Zhu H, Butera M, Nelson D, Liu C. Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication. Virology Journal 2005, 2: 80. PMID: 16146571, PMCID: PMC1232870, DOI: 10.1186/1743-422x-2-80.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntiviral AgentsBase SequenceCell LineGenes, MHC Class IHepacivirusHepatitis CHumansInterferon Regulatory Factor-1Interferon Type IInterferon-alphaInterferon-Stimulated Gene Factor 3Interleukin-10InterleukinsJanus KinasesMolecular Sequence DataRNA, ViralSignal TransductionSTAT Transcription FactorsVirus ReplicationConceptsInterferon-stimulated genesIL-28AAntiviral activityAntiviral efficacyHuman hepatoma cellsSide effectsChronic hepatitis C viral infectionHepatitis C viral infectionViral RNA replicationAntiviral response ratesHCV subgenomic RNA replicationIFNα-based therapyGenotype 1 infectionHCV chronic infectionC viral infectionIL-10 receptorIL-10 treatmentHLA class IType I IFNJAK-STATRNA replicationDose-dependent mannerHepatoma cellsExpression of ISGsUndesirable side effects
2004
An immunomodulatory role for CD4+CD25+ regulatory T lymphocytes in hepatitis C virus infection
Cabrera R, Tu Z, Xu Y, Firpi R, Rosen H, Liu C, Nelson D. An immunomodulatory role for CD4+CD25+ regulatory T lymphocytes in hepatitis C virus infection. Hepatology 2004, 40: 1062-1071. PMID: 15486925, DOI: 10.1002/hep.20454.Peer-Reviewed Original ResearchMeSH KeywordsAntibodiesAntibody FormationAntigens, CDCase-Control StudiesCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell CommunicationEpitopesHepatitis CHepatitis C AntigensHumansImmune SystemInterleukin-10PhenotypeReceptors, Interleukin-2Transforming Growth Factor betaTransforming Growth Factor beta1ConceptsHepatitis C virus infectionPeripheral blood mononuclear cellsC virus infectionRegulatory T lymphocytesBlood mononuclear cellsT lymphocytesMononuclear cellsVirus infectionHCV-specific T-cell responsesCell-cell contact mannerT cell immune responsesHCV RNA titersT cell frequenciesIL-10 productionT cell responsesCell immune responsesInterferon-gamma productionLiver inflammatory activityNormal control subjectsT cell proliferationInterferon gamma activityGrowth factor betaIL-10Intracellular cytokinesInflammatory activityOne‐year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection
Firpi R, Abdelmalek M, Soldevila‐Pico C, Cabrera R, Shuster J, Theriaque D, Reed A, Hemming A, Liu C, Crawford J, Nelson D. One‐year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transplantation 2004, 10: 1240-1247. PMID: 15376304, DOI: 10.1002/lt.20238.Peer-Reviewed Original ResearchConceptsProtocol liver biopsiesRapid fibrosis progressionLiver transplant recipientsFibrosis progressionDonor ageLiver biopsyTransplant recipientsCytomegalovirus infectionUnits/yearMedian fibrosis progression rateRecurrent hepatitis C infectionHepatitis C virus infectionC virus infectionDevelopment of cirrhosisFibrosis progression rateHepatitis C infectionSurgery-related variablesRate of progressionDevelopment of fibrosisDeterminants of progressionGraft lossKnodell systemRecurrent HCVRejection episodesYear posttransplantSustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C
Abdelmalek M, Firpi R, Soldevila‐Pico C, Reed A, Hemming A, Liu C, Crawford J, Davis G, Nelson D. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transplantation 2004, 10: 199-207. PMID: 14762857, DOI: 10.1002/lt.20074.Peer-Reviewed Original ResearchConceptsHepatitis C virusLiver transplant recipientsTransplant recipientsHepatitis CLiver histologyFibrosis stageHCV RNAViral clearanceViral responseCombination therapyDetectable hepatitis C virusRecurrent chronic hepatitis CRecurrent hepatitis C infectionRecurrent hepatitis C virusDetectable HCV RNASustained viral responseChronic hepatitis CInterferon-based treatmentOrthotopic liver transplantationRecurrent hepatitis CHepatitis C infectionInterferon-based therapyRegression of fibrosisGrade of inflammationBaseline histology
2002
Combination of interferon alfa‐2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C
Firpi R, Abdelmalek M, Soldevila‐Pico C, Reed A, Hemming A, Howard R, van der Werf W, Lauwers G, Liu C, Crawford J, Davis G, Nelson D. Combination of interferon alfa‐2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transplantation 2002, 8: 1000-1006. PMID: 12424712, DOI: 10.1053/jlts.2002.34968.Peer-Reviewed Original ResearchConceptsInterferon alfa-2bLiver transplantationAlfa-2bHistological recurrenceViral eradicationHCV RNAWeek 24Recurrent hepatitis C virus (HCV) infectionHCV RNA 6 monthsHepatitis C virus infectionEnd pointProgressive cholestatic diseaseRecurrent HCV infectionSerum HCV RNAC virus infectionLiver transplant recipientsPrimary end pointRecurrent hepatitis CSecondary end pointsGenotype 1 infectionYears of therapyEnd of treatmentHigh viral loadLiver biopsy resultsRecurrent HCV